Literature DB >> 18240141

JunD suppresses bone formation and contributes to low bone mass induced by estrogen depletion.

Aya Kawamata1, Yayoi Izu, Haruna Yokoyama, Teruo Amagasa, Erwin F Wagner, Kazuhisa Nakashima, Yoichi Ezura, Tadayoshi Hayata, Masaki Noda.   

Abstract

JunD is an activator protein-1 (AP-1) component though its function in skeletal system is still not fully understood. To elucidate the role of JunD in the regulation of bone metabolism, we analyzed JunD-deficient mice. JunD deficiency significantly increased bone mass and trabecular number. This bone mass enhancement was due to JunD deficiency-induced increase in bone formation activities in vivo. Such augmentation of bone formation was associated with simultaneous increase in bone resorption while the former was dominant over the latter as accumulation of bone mass occurred in JunD-deficient mice. In a pathological condition relevant to postmenopausal osteoporosis, ovariectomy reduced bone mass in wild type (WT) mice as known before. Interestingly, JunD deficiency suppressed ovariectomy-induced increase in bone resorption and kept high bone mass. In addition, JunD deficiency also enhanced new bone formation after bone marrow ablation. Examination of molecular bases for these observations revealed that JunD deficiency enhanced expression levels of c-jun, fra-1, and fra-2 in bone in conjunction with elevated expression levels of runx2, type I collagen, and osteocalcin. Thus, JunD is involved in estrogen depletion-induced osteopenia via its action to suppress bone formation and to enhance bone resorption.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18240141     DOI: 10.1002/jcb.21660

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  16 in total

1.  c-Jun is required for the specification of joint cell fates.

Authors:  Akinori Kan; Clifford J Tabin
Journal:  Genes Dev       Date:  2013-03-01       Impact factor: 11.361

Review 2.  Multiple endocrine neoplasia type 1 revealed by a hip pathologic fracture.

Authors:  Maroua Slouma; Maissa Abbes; Rim Dhahri; Noureddine Litaiem; Nour Gueddiche; Nada Mansouri; Issam Msekni; Imen Gharsallah; Leila Metoui; Bassem Louzir
Journal:  Clin Rheumatol       Date:  2020-07-14       Impact factor: 2.980

Review 3.  Molecular genetic studies of gene identification for osteoporosis: the 2009 update.

Authors:  Xiang-Hong Xu; Shan-Shan Dong; Yan Guo; Tie-Lin Yang; Shu-Feng Lei; Christopher J Papasian; Ming Zhao; Hong-Wen Deng
Journal:  Endocr Rev       Date:  2010-03-31       Impact factor: 19.871

4.  Polyamines regulate the stability of JunD mRNA by modulating the competitive binding of its 3' untranslated region to HuR and AUF1.

Authors:  Tongtong Zou; Jaladanki N Rao; Lan Liu; Lan Xiao; Ting-Xi Yu; Ping Jiang; Myriam Gorospe; Jian-Ying Wang
Journal:  Mol Cell Biol       Date:  2010-08-30       Impact factor: 4.272

Review 5.  Regulation of gene expression in osteoblasts.

Authors:  Eric D Jensen; Rajaram Gopalakrishnan; Jennifer J Westendorf
Journal:  Biofactors       Date:  2010 Jan-Feb       Impact factor: 6.113

6.  Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production.

Authors:  Aline Bozec; Latifa Bakiri; Maria Jimenez; Thorsten Schinke; Michael Amling; Erwin F Wagner
Journal:  J Cell Biol       Date:  2010-09-13       Impact factor: 10.539

Review 7.  Inherited Defects of the ASC-1 Complex in Congenital Neuromuscular Diseases.

Authors:  Justine Meunier; Rocio-Nur Villar-Quiles; Isabelle Duband-Goulet; Ana Ferreiro
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

8.  The immediate early gene product EGR1 and polycomb group proteins interact in epigenetic programming during chondrogenesis.

Authors:  Frank Spaapen; Guus G H van den Akker; Marjolein M J Caron; Peggy Prickaerts; Celine Rofel; Vivian E H Dahlmans; Don A M Surtel; Yvette Paulis; Finja Schweizer; Tim J M Welting; Lars M Eijssen; Jan Willem Voncken
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

Review 9.  Post-surgical follow-up of primary hyperparathyroidism associated with multiple endocrine neoplasia type 1.

Authors:  Flavia L Coutinho; Delmar M Lourenco; Rodrigo A Toledo; Fabio L M Montenegro; Sergio P A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

10.  Bone phenotypes in multiple endocrine neoplasia type 1: survey on the MEN1 Florentine database.

Authors:  Francesca Marini; Francesca Giusti; Teresa Iantomasi; Federica Cioppi; Maria Luisa Brandi
Journal:  Endocr Connect       Date:  2022-05-11       Impact factor: 3.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.